Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$45.33 USD
-1.56 (-3.33%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $45.30 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 61 - 80 ( 85 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Steady Progress With Acrobat Readouts Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Which Endocrine Companies to See and Why at Our 32nd Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Expectations Going Into Ph1 PK/PD Data for CRN01941 in 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $37/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $37/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Another Quarter of Quiet Execution, POC for Key Programs Upcoming in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Update Serves as a Reminder That Crinetics Is More than Acromegaly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Dinner on Emerging Therapies for Acromegaly
Provider: H.C. Wainwright & Co., Inc.